

Sunday, November 1, 2009**Room**

14:00-16:30	Opening Ceremony	<i>Tsavo Ballroom</i>
-------------	-------------------------	-----------------------

Monday, November 2, 2009**Room**

07:00-17:00	Registration	
-------------	---------------------	--

07:00-19:00	Internet Access	<i>Safari Lounge</i>
-------------	------------------------	----------------------

07:00-18:00	Speaker Ready Room	<i>Caucus 104 (First Floor)</i>
-------------	---------------------------	-------------------------------------

07:30-19:00	Press Room	<i>Magadi</i>
-------------	-------------------	---------------

07:00-08:00	Poster Session A Set-Up Posters 309-328, 497-511, 538-545, 552-562, 563-592, 689-703, 720-139	<i>Delegates Lounge (First Floor)</i>
-------------	---	---

Plenary 1:		<i>Tsavo Ballroom</i>
-------------------	--	-----------------------

08:15-08:45	Mainstreaming the Research Agenda: Building Blocks of the Global Malaria Action Plan	
-------------	--	--

08:45-09:15	The importance national leadership in the fight against malaria	
-------------	---	--

09:15-09:30	TBA	
-------------	-----	--

09:30-10:15	Malaria and the epidemiological transition in Africa	
-------------	--	--

10:15-10:45	Coffee Break	<i>Delegates Lounge (First Floor)</i>
-------------	---------------------	---

10:15-10:45	Poster Session A Viewing Posters 309-328, 497-511, 538-545, 552-562, 563-592, 689-703, 720-139	<i>Delegates Lounge (First Floor)</i>
-------------	--	---

10:15-19:00	Exhibitions Open	<i>The Courtyard</i>
-------------	-------------------------	----------------------

Symposium 1:	Quest for blood stage antigens and the readout methods correlating with protection	<i>Taifa</i>
---------------------	---	--------------

10:45-11:00	Biomarkers of Natural Immunity to Falciparum Malaria in Endemic Populations: Rationales and Biases in Antigen, Immune Assay, and Population Selection	
-------------	---	--

11:05-11:20	Identifying the targets and defining the mechanism of action of protective antibodies against P. falciparum	
-------------	---	--

11:25-11:40	Measuring immune responses to P. falciparum antigens and their correlation with protection	
-------------	--	--

11:45-12:00	GIA, ELISA and Protection	
-------------	---------------------------	--

12:05-12:20	A novel approach to malaria vaccine discovery: presentation of the concept and evidence for practical feasibility	
-------------	---	--

12:25-12:40	Multi-faceted impact of MSP-1p42 specific antibodies on blood stages of P. falciparum	
-------------	---	--

12:45-13:00	Heterologous prime-boost immunizations with different alleles of MSP1 as strategy to overcome allele-specific immunity	
-------------	--	--

13:00-13:15	GIA Proficiency Panel	
-------------	-----------------------	--

Symposium 2:	Traditional medicines for malaria	<i>Batian</i>
---------------------	--	---------------

10:45-11:05	Plants for prophylaxis? Directions for future research	
-------------	--	--

11:05-11:25	Local use of Artemisia annua for the treatment of malaria: experiences and challenges	
-------------	---	--

1

Sunday, November 1



11:25-11:45	COMBAT: COMBined Artemisia Therapy for the treatment of malaria
11:45-12:05	Involving school students in ethnobotanical research
12:05-12:25	Traditional medicines and severe malaria in Mali
12:25-12:45	Development of a traditional antimalarial for use in malaria control programmes: Argemone mexicana in Mali
12:45-13:05	Perspectives of a malaria expert

Symposium 3: Entomological monitoring of vector control activities under the US President's Malaria Initiative

10:45-13:15 *Lake Turkana*

Scientific Session 1: Treatment and Control : Case Management

Tsavo Ballroom 3

10:50-11:05	1	Comparison of two strategies for the delivery of ...
11:05-11:20	2	Establishing a surveillance system to measure childhood ...
11:20-11:35	3	Impact of zinc and vitamin A supplementation on malaria incidence and nutritional status ...
11:35-11:50	4	Malaria morbidity and drug policies in Dielmo ...
11:50-12:05	5	Pilot Implementation of intermittent preventive..
12:05-12:20	6	Synergistic effects of home-management and intermittent preventive treatment of ...
12:20-12:35	7	Mathematical modelling for malaria elimination
12:35-12:50	8	BLACKWATER FEVER AN IMPORTANT CAUSE OF ACUTE RENALE FAILURE IN CONGOLESE PEDIATRIC POPULATION

Scientific Session 2: Pathogenesis I

Lenana

10:50-11:05	9	MALARIA AND HELMINTHIC INFECTIONS ALONGSIDE HAEMOGLOBIN LEVELS AMONGST SCHOOL CHILDREN IN BELLO SUB-DIVISION CAMEROON
11:05-11:20	10	A biallelic dinucleotide microsatellite repeat (TA repeat) at -906 ...
11:20-11:35	11	A functional COX-2 gene promoter polymorphism (-765G>C) is associated with ...
11:35-11:50	12	Complement Regulatory Protein Levels, Immune Complex Binding Capacity...
11:50-12:05	13	Complement Utilization in Children with Severe Malarial Anemia
12:05-12:20	14	Elevation of HMGB1 in Ugandan children with Plasmodium falciparum malaria
12:20-12:35	15	Erythrocyte CR1/CD35 Inhibits...
12:35-12:50	16	Impact of artemisinin-based combination therapy on malaria transmission in Mali
12:50-13:05	17	Role of Lipid profile on pathogenesis of malaria

Scientific Session 3: Parasite Biology I

Tsavo Ballroom 2

10:50-11:05	18	Role of TCA cycle enzymes in Plasmodium falciparum
11:05-11:20	19	SURFINs of Plasmodium falciparum
11:20-11:35	20	A codon-harmonised approach for the improvement of heterologous expression of two plasmodial proteins
11:35-11:50	21	A functional genomic approach to investigate the effect of polyamine depletion induced by the inhibition of S-adenosylmethionine decarboxylase in the human malaria parasite

11:50-12:05	22	Plasmodium falciparum cytosolic Hsp70; a spoke in the wheel of the parasite's survival and pathogenicity	<i>Tsavo Ballroom 2</i>
12:05-12:20	23	Use of ICT Mal Pf rapid diagnostic test cassettes for polymerase chain reaction (PCR) analysis of Plasmodium falciparum rna analysis in Zambia	
12:20-12:35	24	Eosin-5-maleimide and lectin binding are modified in Plasmodium-infected RBCs	
12:35-12:50	25	Comparison of field-based xenodiagnosis and laboratory assays for estimating malaria parasite infectivity to mosquitoes in Western Burkina Faso	

Scientific Session 4: Drugs and Resistance: Clinical Trials I *Tsavo Ballroom 1*

10:50-11:05	26	Open-label Randomised Trial of a fixed dose combination of Artemisinin and Naphthoquine for ...	
11:05-11:20	27	Auditory function following antimalarial treatment in patients with uncomplicated Plasmodium falciparum malaria...	
11:20-11:35	28	Clinical Efficacy and Safety of Amodiaquine+Artesunate(Arsucam) and Artemether-Lumefantrine(Coartem)...	
11:35-11:50	29	Phase III Pivotal Trial of Pyronaridine Artesunate versus Artemether Lumefantrine in acute uncomplicated Plasmodium falciparum malaria	
11:50-12:05	30	Phase III Pivotal Trial of Pyronaridine Artesunate versus Artemether Lumefantrine in pediatric patients with acute uncomplicated Plasmodium falciparum malaria	
12:05-12:20	31	Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children	
12:20-12:35	32	Phase III Pivotal Trial of Pyronaridine Artesunate versus Mefloquine plus Artesunate in patients with acute uncomplicated Plasmodium falciparum malaria	
12:35-12:50	33	Comparative efficacy of Sulfadoxine – Pyrimethamine + amodiaquine vs. sulfadoxine-pyrimethamine+artesunate vs. sulfadoxine-pyrimethamine alone on uncomplicated falciparum malaria in Mali.	
12:50-13:05	34	A phase II randomized, double-blind study to compare the efficacy, safety, tolerability, and pharmacokinetics of two regimens using intravenous artesunate in African children with severe malaria	

Scientific Session 5: Vaccines I *Aberdares*

10:50-11:05	35	A vaccine against pregnancy-associated malaria based on a single DBL domain of VAR2CSA	
11:05-11:20	36	Analysis of T-cell responses against UB05 and synthetic peptides of plasmodium falciparum	
11:20-11:35	37	Asexual blood-stage antibody responses in children vaccinated with RTS,S/AS02A in Mozambique	
11:35-11:50	38	Assessment of the ability of antibody reagents with specificity against VAR2CSA to inhibit binding of Plasmodium falciparum isolates from pregnant women to chondroitin sulfate A	
11:50-12:05	39	CD8+ T cell Responses to Novel Liver Stage Antigens of P. falciparum in Naturally Exposed Individuals	
12:05-12:20	40	Design of second generation Pan-reactive Apical Membrane Antigen-1 (AMA1) vaccine against Plasmodium falciparum malaria.	
12:20-12:35	41	Double blind, randomized, phase IIb study to evaluate the immunogenicity, safety, and efficacy of Plasmodium falciparum vaccine candidate, Merozoite Surface Protein-3 Long synthetic peptide (MSP3) adjuvanted in aluminium hydroxide versus VERORAB in healt	
12:35-12:50	42	Extended follow up of a phase IIb, randomized controlled trial to assess efficacy, safety and immunogenicity of the candidate malaria vaccine RTS,S/AS01 in 5-17 months old children in Kilifi, Kenya.	
12:50-13:05	43	Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months	

Scientific Session 6:	Socio-Economic Aspects		<i>Shimba</i>
10:50-11:05	44	Health-seeking behaviour and the cost of presumptive diagnosis compared to rapid diagnostic testing in malaria treatment in South East Nigeria in the era of combination therapy	
11:05-11:20	45	Community Participation in Malaria Management in Mali	
11:20-11:35	46	Evaluation of awareness, accessibility and use of malaria control interventions in Ogun State, Nigeria	
11:35-11:50	47	Immediate neuropsychological and behavioral benefits of computerized cognitive rehabilitation in Ugandan pediatric cerebral malaria survivors	
11:50-12:05	48	Are malaria treatment expenditures catastrophic to different socio-economic and geographic groups and how do they cope with payment? A study in southeast Nigeria	
12:05-12:20	49	Financial impact of new antimalarial combination on health insurance	
12:20-12:35	50	Studies on visual instructions to improve patient understanding of malaria treatment through public and private health providers in East Africa	
12:35-12:50	51	A DECISION ANALYTIC APPROACH TO ASSESSING POLICY TRADEOFFS IN MALARIA CONTROL IN TANZANIA	
12:50-13:05	52	Willingness to pay for Rapid Diagnostic Test (RDT) for Malaria in the Southeast, Nigeria	
Scientific Session 7:	Genomics I		<i>Amphitheatre</i>
10:50-11:05	53	ace-1 duplication in Anopheles gambiae: a challenge for malaria control	
11:05-11:20	54	Analysis of signal transduction pathways in pathogenesis of Plasmodium falciparum malaria	
11:20-11:35	55	Transcriptional regulation in field isolates of Plasmodium falciparum	
11:35-11:50	56	Surveying Genetic Diversity in Plasmodium falciparum	
12:05-12:20	57	Phylogenetic and bioinformatics analysis of cytochrome P450 super gene family from Anopheles gambiae	
11:50-12:05	58	Low linkage disequilibrium in Anopheles gambiae s.l . populations	
12:20-12:35	59	The variant-ome of Plasmodium falciparum	
12:35-12:50	60	Genetic polymorphism in odorant binding proteins (OBP-olfac) genes between incipient species of the African malaria vector Anopheles gambiae	
12:50-13:05	61	Polymorphisms in Anopheles gambiae immune genes show association to malaria resistance	
13:15-14:30	Lunch		<i>Marquee (in the Lawn)</i>
13:15-14:30	Poster Session A Viewing Posters 309-328, 497-511, 538-545, 552-562, 563-592, 689-703, 720-139		<i>Delegates Lounge (First Floor)</i>
10:15-19:00	Exhibitions open		<i>The Courtyard</i>
Symposium 4:	Toward Genomic Epidemiology of Malaria: Progress, Challenges, and Potential		<i>Tsavo Ballroom3</i>
14:45-15:00		Overview of genomic epidemiology of malaria and its application within the MalariaGEN Programme	
15.00-15.15		Genomic epidemiology and the Plasmodium genome	

15.15-15.30	Using genome epidemiology to assess factors associated with protection from severe malaria
15.30-15.45	Human genetic factors associated with antibody levels and malaria parasite infections
15.45-16: 30	During this session summary results will be presented from across the MalariaGEN network and a discussion will be facilitated focused on strengthening scientific research networks and capacity building

Symposium 5: The President's Malaria Initiative (PMI): A collaborative approach to support National Malaria Control Programs in Africa *Shimba*

14:30-15:00	The President's Malaria Initiative: a collaborative approach to scaling up malaria control interventions
15:00-15:30	PMI contributions to reaching Roll Back Malaria targets in Africa
15:30-16:00	Scaling up indoor residual spraying in Ghana
16:00-16:30	Successes and future strategy for the scale-up of long-lasting insecticide treated nets (LLINs) in Mozambique

Symposium 6: New trends in the development of DHA-PQP (Duo- Cotecxin®) *Batian*

Symposium 7: Understanding the Antimalarials Market: improving evidence to guide interventions *Amphitheatre*

Introduction to the Symposium (5 mins)	
	Introduction to the Symposium (5 mins)
	Why focus on the market? (20 mins)
	Using market data to improve global health initiatives (20 mins)
	Sizing the market (20 mins)
	Understanding what happens at the last mile
	Discussion and conclusion (10 mins)

Symposium 8: PDPs 10 years on: challenges and opportunites *Lenana*

14:30-14:35	Introduction
14:35-14:45	African Perspective
14:45-15:05	Vector Control
15:05-15:25	Effective Collaborations, Successful Delivery: Ten Years of MMV
15:25-15:45	Malaria Vaccine Research & Development: Past, Present, and Future
15:45 - 16:30	Moderated Q & A session

Sumposium 9: Improving Malaria Diagnostics Quality and Adherence to Results *Taiya*

Overview, Global Guidance on Diagnostics Testing and Key Components of a Diagnostics Program	
Developing Sustainable Quality Assurance and Quality Control Programs for Malaria RDTs	
Assuring Quality of Malaria Microscopy	
Appropriate Use of Diagnostic Testing and Adherence to Test Results	
Outreach Supervision & On-the-job Training of Laboratory and Clinical Staff	



Symposium 44:	Advancing and Optimizing Malaria Therapy with the Promise of Multiple First Line Options		<i>Lake Turkana</i>
		Multiple First-Line Treatments (MFT): Why is it critical and how can it be implemented?	
		Latest advancements in the treatment of uncomplicated malaria from a Public Health perspective.	
		High quality malaria treatments - Why does it matter and how can it be ensured?	
		The Informed Patient, Caregiver and Provider: How can we promote better treatment outcomes?	
Scientific Session 8:	Vector Biology and Control		<i>Tsavo Ballroom 1</i>
	14:35-14:50	62 Preliminary results of three years studies of impact of washing practices on the longevity and duration of efficacy of the Long Lasting Impregnated nets (LLINs)...	
	14:50-15:05	63 PHYSICAL AND INSECTICIDAL DETERIORATION OF BEDNETS AFTER 3 - 6 MONTHS HOUSEHOLD USE IN RURAL ETHIOPIA	
	15:05-15:20	64 Mosquitoes and bed nets: testing the spatial positioning of insecticide on nets and the rationale behind combination insecticide treatments	
	15:20-15:35	65 The Development of a new Long Lasting Impregnated net	
	15:35-15:50	66 A modeling approach to evaluate distribution strategies for universal ITN coverage	
	15:50-16:05	67 Monitoring and evaluating the impact of Indoor Residual Spraying in Zambezia Province, Mozambique.	
	16:05-16:20	68 Indoor residual spraying for preventing malaria – a Cochrane review	
	16:20-16:35	69 Indoor use of carbamate treated plastic sheeting in combination with long lasting insecticidal nets to control pyrethroid resistant malaria vectors	
	16:35-16:50	70 Integrated Mosquito Control Using Community Based Adaptive Techniques in Urban Malindi, Kenya	
	16:50-17:05	71 Laboratory assessment of the entomopathogenic fungi <i>Beauveria bassiana</i> and <i>Metarhizium anisopliae</i> ...	
Scientific Session 9:	Health System Research		<i>Aberdares</i>
	14:35-14:50	72 Examining implementation experiences of public health interventions...	
	14:50-15:05	73 The implications of cost on acceptance of referral advice after pre-referral treatment of severe malaria...	<i>Aberdares</i>
	15:05-15:20	74 Acceptability of Rapid Diagnostics Test (RDT) and pre-packed drug (Coartem) through community based volunteers...	<i>Aberdares</i>
	15:20-15:35	75 Malaria SOS: a web-based data integration application for malaria surveillance	<i>Aberdares</i>
	15:35-15:50	76 Evaluating the Impact of Subsidized Artemether-Lumefantrine (AL) in the Retail Sector...	<i>Aberdares</i>
	15:50-16:05	77 A systematic review of the accuracy of rapid diagnostic tests for malaria in endemic areas	<i>Aberdares</i>
	16:05-16:20	78 Using geographic information systems to improve the interpretation of malaria data from clinics in Kenya	<i>Aberdares</i>
Scientific Session 10:	Immunology APC		<i>Tsavo Ballroom 2</i>
	14:35-14:50	79 Characterization of antigen presenting cell subsets and their activation in parasitized and non-parasitized ...	
	14:50-15:05	80 Phenotype and parasite inhibitory activity of blood monocytes in acute uncomplicated ...	
	15:05-15:20	81 Modulation of the monocyte scavenger receptor CD36 expression and nonopsonic	
	15:20-15:35	82 EXPRESSION OF Fc̳RIII BY MONOCYTES FROM CHILDREN WITH PLASMODIUM FALCIPARUM ...	

15:35-15:50	83	Malaria and CD36: beta1 integrin stably associates with CD36 in mouse macrophages...	
15:50-16:05	84	B cell responses in the presence of Plasmodium falciparum infection	
16:05-16:20	85	B cell activity in children with malaria	
16:20-16:35	86	Adjuvant induced immune responses in populations living in a malaria endemic area	
16:30-17:00	Coffee Break		<i>Delegates Lounge (First Floor)</i>
16:30-17:00	Poster Session A Viewing	Posters 309-328, 497-511, 538-545, 552-562, 563-592, 689-703, 720-139	<i>Delegates Lounge (First Floor)</i>
Controversies I:	Presumptive Treatment for Malaria: time for a change?		<i>Amphitheatre</i>
17:00-18:30			
Symposium 11:	Pharmacovigilance of new antimalarials in the field: challenges and initiatives		<i>Aberdares</i>
17:00-19:00		Counterfeit antimalarial medicines	
		Pharmacovigilance in Africa: challenges and opportunities	
		The ASAQ monitoring plan	
		Large scale safety study in Liberia.	
		Antimalarials comparative cohort studies.	
		The Côte d'Ivoire antimalarial implementation study.	
Symposium 12:	Intermittent Preventive Treatment of malaria in infants (IPTi): a new tool for national malaria control programs		<i>Lenana</i>
17:00-19:00		Summary of main research results and current policy status – WHO	
		Feasibility and community effects of large-scale IPTi implementation in southern Tanzania	
		Experience from pilot implementation by UNICEF in 6 African countries	
		The cost effectiveness of IPTi	
		Tool to help determine where to implement IPTi	
		Round table discussion on next steps for a country to choose to implement IPTi	
		Summary of main research results and current policy status – WHO (5 mins presentation + 5 mins for questions)	

Tuesday, November 3, 2009

Room

07:00-17:00	Registration	
07:00-19:00	Internet Access	Safari Lounge
07:00-18:00	Speaker Ready Room	Caucus 104 (First Floor)
07:30-19:00	Press Room	Magadi
07:00-08:00	Poster Session B Set-Up Posters 291, 375-403, 473-477, 478-499, 512-526, 546-550, 593-622, 740-759	Delegates Lounge (First Floor)
Plenary 2:		Tsavo Ballroom
08:15-08:40	Malaria: Policy and Advocacy Issues	
08:40-09:05	Health System research	
09:05-09:30	Health Research Ethics in Public Health	
09:30-09:55	Treatment and Control	
09:55-10:20	Research Capacity in Malaria: a Shared Long-term Responsibility	
10:15-10:45	Coffee Break	Delegates Lounge (First Floor)
10:15-10:45	Poster Session B Viewing Posters 291, 375-403, 473-477, 478-499, 512-526, 546-550, 593-622, 740-759	Delegates Lounge (First Floor)
10:15-19:00	Exhibitions Open	The Courtyard
Symposium 13:	Early Stage Drug Discovery	Amphitheatre
10:45-11:05	Discovering & developing antimalarial drugs in Africa by Africans...	
11:05-11:15	Questions	
11:15-11:25	Targeting mutant PfCRT in antimalarial drug development	
11:25-11:30	Questions	
11:30-11:40	Role of heme in the antimalarial activity of peroxide-containing drugs	
11:40-11:45	Questions	
11:45-11:55	Modulation of the monocyte scavenger receptor CD36 expression ...	
11:55-12:00	Questions	
12:00-12:10	Assessment of Plasmodium falciparum tyrosine kinase-like (TKL)...	
12:10-12:15	Questions	
12:15-12:25	Potential of Methotrexate in the treatment of malaria	
12:25-12:30	Questions	
12:30-12:40	Multiple targets of antimalarial bis-cations and delayed parasite death	
12:40-12:45	Questions	
12:45-12:55	Synthesis of fluorescent, biotinylated and radiolabelled antimalarial endoperoxides...	
12:55-13:00	Questions	

∞

Tuesday, November 3

	13:00-13:10		Antimalarial activity and cytotoxicity of crude extracts from three plants used in traditional medicine...	
	13:10-13:15		Questions	
Symposium 14:	GMZ2 Symposium on Malaria Vaccines			<i>Shimba</i>
	10:45-10:50		Introduction of Symposium	
	10:50-11:10		The rational selection of the two subcomponents, GLURP and MSP3, in the GMZ2 candidate vaccine	
	11:10-11:20		Outcome of the Phase I clinical trials of the individual components, GLURP and MSP3	
	11:20-11:40		Results - Phase Ia Clinical Trial in German adults	
	11:40-12:00		Results - Phase Ib Clinical Trial in Gabonese adults	
	12:00-12:20		Results - Phase Ib dose finding pediatric trial in Gabonese children	
	12:20-12:40		Results – Baselines studies in preparation for the proposed Phase IIb Multicenter efficacy clinical trial	
	12:40-13:00		Clinical Development strategy & the planned Multicenter Phase IIb efficacy clinical trial	
	13:00-13:10		General discussion	
	13:10-13:15		Concluding remarks	
Symposium 15:	Coartem®: Malaria diagnosis, treatment and patient benefit from community deployment			<i>Taifa</i>
			Community-based deployment of Coartem® in Ethiopia: Impact and implications for other rural regions of Africa	
			Pharmacovigilance in the ALIVE study – a model for safety monitoring in a resource-constrained environment	
			A prospective observational study of Coartem® in pregnancy	
			Optimising community-based use of Coartem®: Role Model Mothers	
			Achieving effective home-based management of malaria	
Symposium 16:	Accessing ACTs I: Current Evidence			<i>Lake Turkana</i>
	10:45-11:25		Findings from ACTwatch in 7 countries...	
	11:25-11:40		Evidence from other studies on ACT availability...	
	11:40-12:10		Findings from AMFm-like pilots:Tanzania and Uganda	
	12:10-12:45		Discussion	
Symposium 17:	Intermittent preventive treatment of malaria in children			
	10:45-11:30		A trial of IPTc in children sleeping under an ITN in Burkina Faso and Mali: Background and study design; Results from Burkina Faso; Results from Mali	<i>Batian</i>
	11:30-12:00		A phased introduction of IPTc in Senegal: Study design and implementation; Preliminary results	
	12:00-12:20		IPTc and Home Management of Malaria in The Gambia	
	12:20-12:50		The IPTc Task Force	
	12:50-13:15		General discussion	
Scientific Session 11:	Vector Behaviour			<i>Tsavo Ballroom1</i>
	10:50-11:05	87	Field evaluation of three commercial repellent formulations against malaria mosquitoes of a forest area in Cameroon	
	11:05-11:20	88	Why do African malaria vectors specialize on humans or cattle over alternative hosts?	

11:20-11:35	89	The effect of Mosquito Magnet Liberty Plus™ traps on the human mosquito biting rate under semi-field conditions.
11:35-11:50	90	Behavioral studies of the chromosomal forms of Anopheles funestus from Burkina Faso
11:50-12:05	91	Molecular bases of post-mating behaviour in Anopheles gambiae females
12:05-12:20	92	Comparing prey behavioural responses to predation in the M and S forms...
12:20-12:35	93	Swarming and mating behaviour of the M and S molecular forms of Anopheles gambiae ...
12:35-12:50	94	Can topical mosquito repellents prevent malaria in Africa?

Scientific Session 12: Immunology: Pregnancy Associated Malaria *Lenana*

10:50-11:05	95	Pregnancy induces malaria recrudescence in immunized mice
11:05-11:20	96	Cellular immunological responses in pregnancy associated malaria
11:20-11:35	97	Phenotyping and levels of activation of dendritic cells (DCs) and monocytes in Pregnancy-Associated Malaria during a follow-up in Benin
11:35-11:50	98	T cells IFN-gamma responses in Pregnancy Associated Malaria during a follow-up in Benin
11:50-12:05	99	Impact of placental malaria on neonatal Treg cells and Plasmodium falciparum-specific immune responses
12:05-12:20	100	Plasmodium falciparum exposure in utero, maternal age and parity influence the innate activation of fetal antigen presenting cells
12:20-12:35	101	Pregnancy-associated malaria affects cord blood TLR ligand-induced cytokine responses
12:35-12:50	102	Cord cytokine levels predict cytokine profiles and malaria hospitalization risk throughout early life
12:50-13:05	103	Effect of intermittent preventive treatment during pregnancy with sulphadoxine-pyrimethamine on maternal and fetal antibody responses against malaria

Scientific Session 13: Epidemiology: Assessment of Malaria Burden *Tsavo Ballroom 2*

10:50-11:05	104	One hundred malaria attacks since birth. A 18-year longitudinal study of malaria morbidity in Dielmo, Senegal
11:05-11:20	105	A Randomized Clinical Trial of the Protective Efficacy of Trimethoprim-Sulfamethoxazole Prophylaxis...
11:20-11:35	106	Immunity to febrile malaria in children: an analysis that distinguishes immunity from lack of exposure
11:35-11:50	107	Réalité du paludisme urbain, à Dakar : paludisme infection et paludisme ressenti
11:50-12:05	108	Serological markers can detect heterogeneity in malaria exposure in an area of very low transmission intensity in Somaliland
12:05-12:20	109	Pregnancy Associated Malaria (PAM) follow-up in Benin: an epidemiological survey

Scientific Session 13: Epidemiology: Assessment of Malaria Burden *Tsavo Ballroom 2*

12:20-12:35	110	Changing malaria epidemiology and susceptibility to pregnancy associated malaria among a cohort of pregnant women in Korogwe, northeastern Tanzania.
12:35-12:50	111	Declining incidence of malaria in a cohort of children living in Kampala Uganda
12:50-13:05	112	Distinct Pattern of Class and Subclass Antibodies in Immune Complexes of Children with Cerebral Malaria and Severe Anaemia due to Plasmodium falciparum Infection
13:05-13:20	113	Failure of ACTs to suppress human infectiousness in a malaria holo-endemic area, Rufiji-Tanzania

Scientific Session 14:	Health Systems Research			<i>Aberdares</i>
10:50-11:05	114	Implementing and sustaining strategies for malaria control through the health system: lessons from the Tanzania Net Voucher Scheme		
11:05-11:20	115	Mapping the private sector supply chain to understand the retail prices and availability of antimalarials in five low-income countries in Africa		
11:20-11:35	116	Predicting the cost-effectiveness of strategies to scale up malaria case management across health system and transmission settings in Sub-Saharan Africa		
11:35-11:50	117	A Snapshot of the Price, Availability and Treatment-Seeking Behavior in the Democratic Republic of Congo		
11:50-12:05	118	Diagnosis of delivery system disorders: an analysis of the delivery of ACTs through the public sector (Kenya), private sector (Ghana), and the community (Senegal)		
12:05-12:20	119	Integrated management of febrile illness in children: how much would confirmation of malaria contribute to improved treatment outcomes?		
12:20-12:35	120	Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system in Uganda		
12:35-12:50	121	Malaria Rapid Diagnosis Performance by Community Health Workers, Zambia		
12:50-13:05	122	Potential cost savings by improving malaria diagnosis in low and moderate transmission settings in Tanzania.		
Scientific Session 15:	Treatment and Control: Prevention			<i>Tsavo Ballroom 3</i>
10:50-11:05	123	Species Identification Errors and False Negative Results		
11:05-11:20	124	The quality of paediatric malaria case-management under artemether-lumefantrine treatment policy in Kenya, Uganda and Zambia		
11:20-11:35	125	Withdrawing antimalarials in febrile children with a negative Rapid Diagnostic Test is safe in moderately and highly endemic areas of Tanzania		
11:35-11:50	126	Affordability leads to dramatic uptake of effective malaria treatment for under fives in Uganda		
11:50-12:05	127	Intermittent preventive treatment during pregnancy reduces neonatal mortality in Mozambique		
12:05-12:20	128	Massive reduction of antimalarial prescription after Rapid Diagnostic Test implementation in Dar es Salaam, Tanzania		
12:20-12:35	129	Residual antimalarials as potential bias in in vivo drug efficacy studies or how unreliable is medical history...		
12:35-12:50	130	Ranking malaria factors to guide malaria control efforts in Africa highlands		
12:50-13:05	131	A retrospective cohort study among pregnant women to measure the effectiveness of current malaria control guidelines...		
13:15-14:30	Lunch			<i>Marquee (in the Lawn)</i>
13:15-14:30	Poster Session B Viewing	Posters 291, 375-403, 473-477, 478-499, 512-526, 546-550, 593-622, 740-759		<i>Delegates Lounge (First Floor)</i>
10:15-19:00	Exhibitions open			<i>The Courtyard</i>
Scientific Session 16:	Treatment and Control			<i>Tsavo Ballroom 3</i>
14:35-14:50	132	Continuous EEG Monitoring and Seizures in Children with Cerebral Malaria		
14:50-15:05	133	Declining Trend of P.falciparum dhfr and dhps Mutation ...		

15:05-15:20	134	Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria...
15:20-15:35	135	Efficacy And Cost-Effectiveness Of Malaria Prevention In Pregnancy In Low And Unstable Transmission: Results of a Randomised Controlled Trial
15:35-15:50	136	High frequency of Plasmodium falciparum CICNI/SGEAA and CVIET haplotypes...
15:50-16:05	137	Hypoglycaemia in severe malaria, aetiological associations and relationship to quinine dosage
Scientific Session 17: Late Breakers		<i>Aberdares</i>
14:30-16:30		
Scientific Session 18: Research Capacity Strengthening		<i>Lenana</i>
14:35-14:50	138	A Participatory Action Research Programme aiming to make conducting malaria trials easier and guide the development of skills for African Clinical Trialists.
14:50-15:05	139	Developing an African Framework for Ethics and Best Practices in Clinical Research: The AfroGuide Project
15:05-15:20	140	Feasibility assessment for the initialization and development of malaria-related computational chemistry research in Sub-Saharan Africa.
15:20-15:35	141	Monitoring adherence to human subject protections in research protocols is a major challenge in post-conflict liberia
15:35-15:50	142	Strengthening clinical trials capacity in africa! The malaria clinical trials alliance perspective.
15:50-16:05	143	Central Africa Network on Tuberculosis, HIV/AIDS and Malaria (CANTAM)
16:05-16:20	144	ISHReCA: Advocating for Health Research Capacity in Africa
Scientific Session 19: Health Research Ethics		<i>Batian</i>
14:35-14:50	145	The Declaration of Helsinki (2008): What researchers in Africa should note
14:50-15:05	146	Application of Good Clinical Practice (GCP) guidelines in African settings
15:05-15:20	147	Experiences with community engagement and informed consent in a genome-wide association study on malaria in Kenya
15:20-15:35	148	Health Research Ethics capacity strengthening in Africa: current situation and prospects
15:35-15:50	149	Iron supplementation for children in malaria-endemic areas: systematic review and meta-analysis
15:50-16:05	150	PABIN/SIDCER Ethical Review Committee Recognition Program in Africa
16:05-16:20	151	Exploring the difficult ethical choices in malaria vector research...
Symposium 18: Improving Access to ACTs II: Malaria case management in a changing Epidemiology		<i>Shimba</i>
14:30-14:50		Treatment and diagnosis: Malaria case management in a changing epidemiology
14:50-15:10		The global ACT subsidy mechanism: Next steps
15:10-15:30		Home-based management of malaria: Scaling up and measuring impact
15:30-15:50		What's in the drug pipeline?
15:50-16:30		Discussion
Symposium 19: WorldWide Antimalarial Resistance Network, WWARN: First steps toward realization		<i>Tsavo Ballroom 2</i>
14:30-14:40		TBA
14:40-15:05		Tools for management of clinical drug efficacy
15:05-15:30		Pharmacology: a key component of assessment of drug efficacy

	15:30-15:55	Molecular tools for surveillance of drug efficacy	
	15:55-16:30	Integrated information on antimalarial resistance...	
Symposium 20:	Monitoring and evaluation of Vector Control		<i>Tsavo Ballroom 1</i>
	14:30-14:50	Integrated Vector Management: Challenges and opportunities for transforming vector control	
	14:50-15:10	Supporting the reorientation of country programs towards IVM: Experiences from the WHO Eastern Mediterranean Region	
	15:10-15:30	Tanzania & Zanzibar experience towards surveillance driven vector management: policy, systems and capacity strengthening issues	
	15:30-15:50	Meeting the challenge of rapid scale up and negotiating private sector involvement in vector control	
Symposium 21:	Poor antimalarial drug quality-Malaria's Deadly		<i>Amphitheatre</i>
	14:30-14:47	Antimalarial drug quality in Africa	
	14:47-15:04	Quality of Drugs Used to Treat Malaria in the Nyanza Province of Kenya	
	15:04-15:21	The State of Antimalarial Medicine Quality in Sub-Saharan Africa: Challenges and Prospects	
	15:21-15:38	Degradation of ACTs, as a result of inadequate storage, leading to questionable quality classification	
	15:38-15:55	New Mass Spec-based Screening Methods used in CODFIN...	
Symposium 22:	Malaria Vaccines		<i>Lake Turkana</i>
	14:30-16:30	Promoting sporozoite and pre-erythrocytic vaccine development	
		One for everyone: Strategies for attenuated Plasmodium liver stages as anti-malaria vaccines.	
		Promoting erythrocytic stage vaccine development	
		Malaria Blood Stages Vaccines: lessons learned and the scientific rationale for next generations	
		Naturally acquired protective responses to blood stage antigens: implications for vaccine development	
Symposium 23:	Malaria in Pregnancy Consortium		<i>Taifa</i>
	14:30-14:32	Introduction to scope of symposium topics; Introduction to first speaker	
	14:32-14:40	Brief introduction to the Malaria in Pregnancy Consortium	
	14:40-14:50	Quantifying the number of pregnancies at risk of malaria in 2007	
	14:50-15:10	Pharmacokinetic studies of antimalarials in pregnancy	
	15:10-15:30	Malaria prevention with IPT-p during pregnancy reduces neonatal mortality	
	15:30-15:50	The effectiveness, cost and cost effectiveness of intermittent preventive treatment...	
	15:50-16:10	A retrospective cohort study among pregnant women to measure the effectiveness of CTX and IPTp...	
	16:10-16:30	Malaria in pregnancy in Malawi 1997-2006...	
	16:30-17:00	Coffee Break	<i>Delegates Lounge (First Floor)</i>
	16:30-17:00	Poster Session B Viewing Posters 291, 375-403, 473-477, 478-499, 512-526, 546-550, 593-622, 740-759	<i>Delegates Lounge (First Floor)</i>
Controversies II:	Attenuated Parasite Vaccines: When and How		<i>Amphitheatre</i>
Symposium 24:	Indoor Residual Spraying, the US President's Malaria Initiative		<i>Impala</i>
	17:00-19:00		

Wednesday, November 4, 2009

Room

	07:00-17:00	Registration	
	07:00-19:00	Internet Access	<i>Safari Lounge</i>
	07:00-18:00	Speaker Ready Room	<i>Caucus 104 (First Floor)</i>
	07:30-19:00	Press Room	<i>Magadi</i>
	07:00-08:00	Poster Session C Set-Up Posters 329-354, 404-433, 469-472, 623-652, 760-779	<i>Delegates Lounge (First Floor)</i>
Plenary 3A:		Malaria Elimination/ Eradication Day	<i>Tsavo Ballroom</i>
	08.15-08.40	History of malaria eradication	
	08.40-08.45	Discussion	
	08.45-08.55	Case Studies of Countries Moving Towards Elimination- Overview & Chair	
	08.55-09.15	a. The Zanzibar Experience	
	09.15-09.35	b. The Rwanda Experience	
	09.35-09.55	c. The Bioko Experience	
	09.55-10.15	Presentation of MEG Prospectus on Elimination	
	10:15-10:45	Coffee Break	<i>Delegates Lounge (First Floor)</i>
	10:15-10:45	Poster Session C Viewing Posters 329-354, 404-433, 469-472, 623-652, 760-779	<i>Delegates Lounge (First Floor)</i>
	10:15-19:00	Exhibitions Open	<i>The Courtyard</i>
Plenary 3B:		Malaria Elimination/ Eradication Day	<i>Tsavo Ballroom</i>
	10.45-10.55	Chair, presentation	
	10.55-11.20	How effective are current tools in the elimination contexts...	
	11.20-11.45	Drugs	
	11.45-12.10	Vaccines	
	12.10-12.35	Vector Control	
	12.35-12.50	Mapping Malaria Risk with a View towards ist Control and Elimination	
	12.50-13.15	Introduction to Malaria Eradication Research Agenda (malERA)...	
	13:15-14:30	Lunch	<i>Marquee (in the Lawn)</i>
	13:15-14:30	Poster Session C Viewing Posters 329-354, 404-433, 469-472, 623-652, 760-779	<i>Delegates Lounge (First Floor)</i>
Symposium 25:		Clinical experience with a new, fixed-dose ACT for the Treatment of Malaria in small children	<i>Lake Turkana</i>
	14:30-14:40	Welcome / Introduction	
	14:40-15:05	Introduction of speakers	

	15:05-15:20	Meta-analysis of paediatric ACTs	
	15:20-15:35	Neuropsychiatric and neurological safety of AS+MQ in children – a new approach	
	15:35-15:50	Efficacy, safety pharmacokinetics of AS+MQ, basic experience from Gabon	
	15:50-16:05	Use of AS+MQ in children – is it safe ?	
	16:05-16:30	General Discussion	
Symposium 26:	Malaria Eradication Research Agenda (malERA)		<i>Lenana</i>
	14.30-14.45	malERA Overview and Context	
	14.45-15.00	Defining the knowledge gaps basic science	
	15.00-15.15	Defining the knowledge gaps tools	
	15.15-15.30	Cross Cutting Themes and Integration	
	15.30-18.30	Guided Feedback/ Discussion	
Symposium 27:	Malaria Vaccine Introduction: Informing Country Level Decision-Making		<i>Taija</i>
	14:30-14:35	Welcome and Introduction	
	14:35-14:55	The Decision-making Framework for the introduction of a malaria vaccine	
	14:55-15:15	Engaging communities in preparation for malaria vaccines	
	15:15-15:35	Economic evaluation alongside a multi-country clinical trial in sub-Saharan Africa	
	15:35-15:55	Modelling as a tool to support decision-making	
	15:55-16:30	Moderated Q & A session	
Symposium 28:	The Affordable Medicines Facility-malaria—AMFm		<i>Impala</i>
	14:30-14:50	Introduction to AMFm: From concept to reality	
	14:50-15:10	Starting up AMFm at the Global Fund	
	15:10-15:25	Pre-deployment experiences in 3 phase 1 countries: Tanzania, Senegal and Nigeria	
	15:25-15:30	Drugs for Neglected Diseases Initiative (development partner for ASAQ)	
	15:30-15:35	UNITAID (major funder)	
	15:35-15:50	Open Discussion	
Symposium 29:	Building Capacity to Use Climate and Environmental Information for Improving Health Outcomes		<i>Batian</i>
	14:30-16:30		
Symposium 30:	ACTs alone are not enough: the importance of Information, Education and Communication		<i>Shimba</i>
	14:30-16:30	Factors impacting the effectiveness of antimalarial interventions	
		A pharmaceutical firm's contribution to IEC on malaria	
		Self-learning based programme in Madagascar and Tanzania: an innovative approach to train future malaria experts	
		Experience drawn from “train the trainers” sessions	
		IEC initiatives for children and communities	
		Community-based IEC initiatives	

Scientific Session 20: Drugs Discovery and Other Molecules			<i>Tsavo Ballroom 1</i>
14:35-14:50	152	Potential of methotrexate in the treatment of malaria	
14:50-15:05	153	New Mass Spec-based Screening Methods used in CODFIN for the Forensic Investigation of Suspected Fake Antimalarial Drugs and Bednets in Less than a Minute.	
15:05-15:20	154	Informing the Evidence Gap in Cambodia: Availability, Price and Provider Practices of Malaria Diagnosis & Treatment	
15:20-15:35	155	Expression of Plasmodium falciparum tubulin; a new anti malarial drug target.	
15:35-15:50	156	Efficacy of antiretroviral 'HAART' regimens on 'Plasmodium berghei' in vivo in mice	
15:50-16:05	157	Discovery and Development of New Antimalarial Drugs: A Novel Academic-Industrial Partnership	
16:05-16:20	158	Pharmacokinetics of sulfadoxine and pyrimethamine in Intermittent Preventive Treatment of malaria in pregnancy (IPTp)	
Scientific Session 21: Treatment and Control: Integrated Control			<i>Tsavo Ballroom 3</i>
14:35-14:50	159	Impact of the introduction of artemether-lumefantrine as first line treatment policy on underfive mortality in two rural districts of Tanzania	
14:50-15:05	160	Intermittent preventive treatment (IPT) in schoolchildren:	
15:05-15:20	161	Intermittent preventive treatment of infants (IPTi) with amodiaquine/ artesunate, SP/artesunate or chlorproguanil-dapsone in western Kenya: a randomized, double-blind placebo-controlled trial	
15:20-15:35	162	Phase II randomised trial of Dextran 70 and Hetastarch for correction of volume deficits in severe malaria	
15:35-15:50	163	A SINGLE BLINDED CLINICAL TRIAL COMPARING ARCO A NEW ANTIMALARIAL DRUG AND COARTEM IN THE TREATMENT OF UNCOMPLICATED MALARIA IN ADULT PATIENTS IN UGANDA	
15:50-16:05	164	Severe sequelae and disability after cerebral malaria in a cohort of Ugandan children attending a specialist neurology clinic	
		Affordability leads to dramatic uptake of effective malaria treatment for under fives in Uganda	
Scientific Session 22: Vector Control and Resistance			<i>Tsavo Ballroom 2</i>
14:35-14:50	165	Identification of P450s involved with insecticide metabolism in Anopheles gambiae	
14:50-15:05	166	Molecular investigations of the effect of a blood meal on insecticide resistance in Anopheles funestus.	
15:05-15:20	167	A Rapid Colorimetric Field Test to Determine Levels of Deltamethrin on PermaNet® Surfaces: Association with mosquito bioactivity.	
15:20-15:35	168	Molecular basis of pyrethroid resistance in Anopheles funestus, major malaria vector in Africa	
15:35-15:50	169	No Title	
15:50-16:05	170	Highly Selective Carbamates Towards the Malaria Mosquito, Anopheles gambiae: Design, Synthesis, Potency and Toxicity Testing.	
16:05-16:20	171	The threat of pyrethroid resistance for control of malaria caused by Anopheles gambiae and the prospect for sustaining insecticidal control using chlorfenapyr and chlorpyrifos methyl	
16:20-16:35	172	Durable Residual Wall Lining (DL): Acceptability, Durability, and Performance for Malaria Vector Management in South Africa	

	16:35-16:50	173	Insecticide susceptibility status of the malaria mosquito: <i>Anopheles gambiae</i> s.l. 17 years after The Gambian Nationwide Insecticide Bed Net Impregnated Program	
	16:50-17:05	174	Insecticide resistance in African malaria vectors: protocols and results from a TDR sponsored network	
Scientific Session 23:	Vector Genetics			<i>Aberdares</i>
	14:35-14:50	175	Ecological divergence between the M and S forms of <i>Anopheles gambiae</i> and the role of chromosomal inversions in local adaptation	
	14:50-15:05	176	Population genetic structure of the malaria vector <i>Anopheles funestus</i> in the senegal river basin, using microsatellite markers	
	15:05-15:20	177	Increasing Frequency of <i>kdr</i> Alleles Associated with Increasing Coverage of Insecticide- treated Bed Nets	
	15:20-15:35	178	Bionomic and population genetic structure of the malaria vector <i>Anopheles moucheti</i> in the equatorial forest region of Africa: an update	
	15:35-15:50	179	Population genetic structure of <i>Anopheles funestus</i> group in Southern Africa	
	15:50-16:05	180	Ontologies and Databases for the Control of Vectors and Disease	
	16:30-17:00		Coffee Break	<i>Delegates Lounge (First Floor)</i>
	16:30-17:00		Poster Session C Viewing Posters 329-354, 404-433, 469-472, 623-652, 760-779	<i>Delegates Lounge (First Floor)</i>
Controversies III:	Malaria Eradication/Elimination			<i>Amphitheatre</i>
	17:00-18:30			
Symposium 31:	Continued demonstration of Coartem® efficacy and safety and the introduction of Coartem® Dispersible			<i>Lenana</i>
	17:00-19:00		Use of Coartem® in children – a pooled analysis of the data	
			Reduced malaria case load with community-based Coartem®: Experience from rural Zambia	
			The vulnerable child: current approaches to the prevention and treatment of malaria	
			Understanding further Coartem® Dispersible	
			Preparing for Coartem® Dispersible: simple strategies for health worker training	
Symposium 43:	Insecticide Resistance Management			<i>Lenana</i>
	17:00-19:00			<i>Aberdares</i>

Thursday, November 5, 2009

Room

	07:00-17:00	Registration	
	07:00-19:00	Internet Access	<i>Safari Lounge</i>
	07:00-18:00	Speaker Ready Room	<i>Caucus 104 (First Floor)</i>
	07:30-19:00	Press Room	<i>Magadi</i>
	07:00-08:00	Poster Session D Set-Up Posters 355-374, 434-468, 529-537, 653-688, 704-719, 780-801	<i>Delegates Lounge (First Floor)</i>
Plenary 4:			<i>Tsavo Ballroom</i>
	08:15-08:40	Being a Committed Partner in the Fight Against Malaria	
	08:40-09:05	Malaria Epidemiology in Africa - current situation	
	09:05-09:30	Malaria Pathogenesis	
	09:30-09:55	B cell response in Malaria	
	09:55-10:20	Evaluation of malaria vaccines in Africa	
	10:15-10:45	Coffee Break	<i>Delegates Lounge (First Floor)</i>
	10:15-10:45	Poster Session D Viewing Posters 355-374, 434-468, 529-537, 653-688, 704-719, 780-801	<i>Delegates Lounge (First Floor)</i>
	10:15-19:00	Exhibitions Open	<i>The Courtyard</i>
Symposium 32:		Endemic Country Capacity building through clinical trials	<i>Shimba</i>
	10:45-10:50	Welcome and Introduction	
	10:50-11:10	Capacity Building: Importance and Challenges	
	11:10-11:30	Research Expertise and Capacity	
	11:30-11:50	Physical Infrastructure	
	11:50-12:10	Management and Communications	
	12:10-13:15	Moderated Q & A session	
Symposium 33:		Health Research Ethics	<i>Amphitheatre</i>
	10:45-10:50	Calling Symposium to order and opening remarks	
	10:50-11:10	Professional indemnity and Insurance of trial participants	
	11:10-11:15	Discussion	
	11:15-11:35	Material Transfer Agreements, use of archived specimens and data sharing in collaborative research	
	11:35-11:40	Discussion	
	11:40-12:00	Genetic and genomic research in Africa	
	12:00-12:05	Discussion	
	12:05-12:25	Technology Transfer and Capacity Strengthening in International Collaborative Research	
	12:25-12:30	Discussion	

	12:30-12:50		Translating research findings into policy and/or interventions	
	12:50-12:55		Discussion	
	12:55-13:15		Closing remarks	
Symposium 34:	Answering key questions on ACT drug delivery in Africa: an introduction to the work of the ACT Consortium			<i>Lake Turkana</i>
	10:45-13:15		Overview of the ACT Consortium (15 mins + 5 mins Q&A)	
			Improving access to ACTs (15 mins + 5 mins Q&A)	
			Improved targeting of ACTs (15 mins + 5 mins Q&A)	
			Monitoring safety of ACTs (15 mins + 5 mins Q&A)	
			Detecting fake ACTs (15 mins + 5 mins Q&A)	
Scientific Session 24:	Parasite Biology: Parasite Genetics			<i>Aberdares</i>
	10:50-11:05	181	The glycosphingolipid pathway as target for new antimalarial drugs	
	11:10-11:25	182	Signals for sequential release of apical organelles during erythrocyte invasion by malaria parasites	
	11:30-11:45	183	Apoptotic machinery in Plasmodium falciparum growing in a continuous culture	
	11:50-12:05	184	Fas-pathway modulation by P. berghei liver stage	
	12:10-12:25	185	Assessment of Plasmodium falciparum Tyrosine Kinase-like (TKL) protein kinases as potential anti-malarial drug targets.	
	12:30-12:45	186	Malaria liver infection is decreased during blood-stage infection	
	12:50-13:05	187	Reverse genetics of the Plasmodium falciparum Aurora-related protein kinase Pfark-1	
Scientific Session 25:	Vector Ecology			<i>Tsavo Ballroom 2</i>
	10:50-11:05	188	Spatial distribution and dynamics of Anopheles gambiae sl larval habitats in the city of Yaoundé, central Cameroon	
	11:05-11:20	189	Larval development of the chromosomal forms of Anopheles funestus in different habitats in Western Burkina Faso: a transplantation experiment.	
	11:20-11:35	190	Urban agriculture and Anopheles habitats in Dar es Salaam, Tanzania	
	11:35-11:50	191	Spatial and temporal distribution of the malaria mosquito Anopheles arabiensis in northern Sudan: influence of environmental factors and implications for vector control	
	11:50-12:05	192	Development of vegetable farming: a cause of the emergence of insecticide resistance in populations of Anopheles gambiae in urban areas of Benin.	
	12:05-12:20	193	Predisposed to adapt? urbanization and diversification of anopheles gambiae in the african equatorial forest	
	12:20-12:35	194	Malaria vector species composition and their role in disease transmission in Mpongwe district of Zambia	
	12:35-12:50	195	Distribution and larval habitat characterization of Anopheles nili and An. moucheti along river networks in southern Cameroon	
	12:50-13:05	196	Ecology of malaria vectors in a highly populated semi arid environment in North-Western Kenya: impact of local environmental modifications on disease outbreaks	
	13:05-13:20	197	Establishment of a Semi-field System for the study of malaria vector ecology in Tanzania	
Scientific Session 26:	Drugs and Resistance			<i>Tsavo Ballroom 1</i>
	10:50-11:05	198	Transmission of Plasmodium falciparum dhfr haplotypes in the Gambia	

11:05-11:20	199	owards understanding the mechanisms of Lumefantrine resistance
11:20-11:35	200	Prevalence of sulfadoxine-pyrimethamine-resistant alleles of Plasmodium falciparum isolates from pregnant women after introduction of IPTp-SP in Gabon.
11:35-11:50	201	Intra-host model of malaria infection: characterizing artesunate resistance
11:50-12:05	202	Molecular monitoring of Plasmodium falciparum drug resistance
12:05-12:20	203	A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria
12:20-12:35	204	IL-22 SNP implications in Clearance of Drug Resistant P. falciparum in Cameroon?
12:35-12:50	205	The search for molecular markers of artemisinin resistance: Implications for Africa

Scientific Session 27:**Vaccines II***Batian*

10:50-11:05	206	Immunoepidemiology approach for the development and optimization of malaria vaccine candidates through a round trip strategy from the lab to the field or the necessary collaboration between basic research and field research
11:05-11:20	207	Interpreting measures of vaccine efficacy from malaria vaccine trials
11:20-11:35	208	MSP-1 Block1/Block2 hybrid: a vaccine candidate against P. falciparum
11:35-11:50	209	Plasmodium falciparum Histidine-Rich Protein 2 ELISA for use in Malaria Intervention Trials
11:50-12:05	210	Randomized, controlled, phase 2b clinical trial to evaluate the safety, immunogenicity and efficacy of WRAIR's AMA-1 malaria vaccine (FMP2.1) adjuvanted in GSK Biologicals' AS02A vs. rabies vaccine in 1-6 year old children in Bandiagara, Mali
12:05-12:20	211	Simian adenoviral malaria vaccine
12:20-12:35	212	The antibody dependent respiratory burst (ADRB) assay is correlated with clinical protection from falciparum malaria, and validates the baculovirus MSP1p19 vaccine candidate.
12:35-12:50	213	A Phase 1 study to assess the safety and immunogenicity of the malaria vaccine candidate MSP3_LSP in children 12-24 months of age living in a stable malaria stable transmission area of Burkina Faso

Scientific Session 28:**Epidemiology and Transmission***Lenana*

10:50-11:05	214	Decreasing Efficacy of Antimalarial Combination Therapy in Uganda Explained by Decreasing Host Immunity Rather than Increasing Drug Resistance
11:05-11:20	215	Evaluation of the public health impact of seasonal IPT in Senegal: study design and description of the study site
11:20-11:35	216	VALIDITY OF VERBAL AUTOPSY PROCEDURES
11:35-11:50	217	Malaria and tick-borne relapsing fever in Senegal : two diseases usually confused
11:50-12:05	218	Development and implementation of a cellular phone-based malaria early epidemic detection system for Zanzibar, 2008
12:05-12:20	219	Impacts of nutritional status on malarial morbidity and mortality among children less than 5 years in Ibadan, South-West Nigeria
12:20-12:35	220	Accounting for treatment in the analysis of longitudinal molecular data of Plasmodium falciparum infections
12:35-12:50	221	Natural factors associated with Plasmodium falciparum infectiousness determined by membrane feeding and QT-NASBA in Burkina Faso

12:50-13:05	222	Using Bayesian methods to validate mathematical models of malaria transmission
13:05-13:20	223	Interruption of malaria transmission in two highland areas of Kenya

Scientific Session 29: Treatment and Control *Tsavo Ballroom 3*

10:50-11:05	224	Comparison of anemia and parasitemia as indicators of malaria control in household and health facility surveys in Malawi
11:05-11:20	225	Integration of Insecticide-Treated Net Distribution into Routine Immunization Services in Malawi
11:20-11:35	226	A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire.
11:35-11:50	227	A randomized open trial of Amodiaquine + Sulfalene-Pyrimethamin vs Artemether-Lumefantrin for the treatment of uncomplicated malaria in Burkina Faso
11:50-12:05	228	A trial of the combined effect of intermittent preventive treatment and insecticide treated bednets in reducing morbidity from malaria in African children
12:05-12:20	229	An intervention to reduce case fatality from severe malaria
12:20-12:35	230	Comparison of the Safety, Tolerability and Efficacy of Three Potential Drug Combinations for Intermittent Preventive Treatment of Malaria in Children-A Randomised Trial.

13:15-14:30 **Lunch** *Marquee (in the Lawn)*

13:15-14:30 **Poster Session D Viewing**
Posters 355-374, 434-468, 529-537, 653-688, 704-719, 780-801 *Delegates Lounge (First Floor)*

Symposium 35: Modelling malaria dynamics: The untapped potential for malaria control programmes *Shimba*

14:30-14:35	Introduction
14:35-14:55	Modelling for malaria control and elimination
14:55-15:15	Modelling antimalarials and transmission
15:15-15:35	Evaluation of home-based malaria management using a Markov model
15:35-15:55	Modelling insecticide resistance, determinants and consequences
15:55-16:15	Integrated models of malaria dynamics
16:15-16:30	Malaria programmes, models and field research

Symposium 36: Integrated Vector Management (IVM) *Batian*

14:30-14:50	Integrated Vector Management: Challenges and opportunities for transforming vector control
14:50-15:10	Supporting the reorientation of country programs towards IVM: Experiences from the WHO Eastern Mediterranean Region
15:10-15:30	Tanzania & Zanzibar experience towards surveillance driven vector management: policy, systems and capacity strengthening issues
15:30-15:50	Meeting the challenge of rapid scale up and negotiating private sector involvement in vector control

Symposium 37: Integrated community case management of malaria, pneumonia and diarrhea *Lake Turkana*

14:30-16:30	
-------------	--



Symposium 38:	Session Two- ANTIMAL: Anti-Malarial Drug Development		<i>Tsavo Ballroom 2</i>
	14:30-14:50	To be confirmed	
	14:50-15:00	Questions	
	15:00-15:10	Effect of dihydroartemisinin (DHA) on human erythroid cell differentiation: Implications for malaria treatment in pregnancy	
	15:10-15:15	Questions	
	15:15-15:25	New approaches for the treatment of severe malaria: bis-thiazolium SAR97276	
	15:25-15:30	Questions	
	15:30-15:40	Novel functionalised benzamidines as potent antimalarial agents	
	15:40-15:45	Questions	
	15:45-15:55	Antiparasitic activities and toxicities of individual enantiomers of 7-chloro-N-[[[(9A)-Octahydro-2H-Quinolizin-1-yl]methyl]-4-Quinolinamine	
	15:55-16:00	Questions	
	16:00-16:10	Towards candidate selection of a novel 1,2,4,5 tetraoxane with antimalarial properties superior to the semi synthetic Artemisinins	
	16:10-16:15	Questions	
	16:15-16:25	The development of effective Novel 4 – aminoquinolines	
	16:25-16:30	Questions	
Symposium 39:	Vectored Vaccines for Malaria		<i>Taifa</i>
	14:30-15:00	Development of a Multi-valent, Multi-stage Adenovirus(Type 5)-Vectored Malaria Vaccine	
	15:00-15:30	Clinical Development of Adenovirus Type 35 Circumsporozoite Malaria Vaccine at NIAID	
	15:30-16:00	Multi-Stage Viral Vector Vaccines using a Heterologous Prime-Boost Approach	
	16:00-16:30	Vectored Malaria Vaccines: Planning For Future Clinical Trials of these Vaccines at African Trial Sites	
Scientific Session 31:	Pathogenesis		<i>Tsavo Ballroom 3</i>
	14:35-14:50	231 Increased deposition of C3b on red cells with low CR1 and CD55 in a malaria-endemic region of western Kenya: implications for the development of severe anemia	
	14:50-15:05	232 Functional IL-10 promoter haplotypes (-1082A/G, -819T/C and -592A/C) condition susceptibility to severe malarial anemia in Kenyan children	
	15:05-15:20	233 Lowered activity of the human erythrocytic pyridoxal kinase - a possible genetic trait offering protection against malaria.	
	15:35-15:50	234 Parasite sequestration in murine model for pregnancy-associated malaria	
	15:50-16:05	235 MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) PROMOTER POLYMORPHISMS AND	
Scientific Session 32:	Roundtable Dialogue With Malaria Funders		<i>Aberdares</i>
	14:30-16:30		
Scientific Session 33:	Vectors		<i>Amphitheatre</i>
	14:35-14:50	236 Malaria vector mapping in East Africa	
	14:50-15:05	237 New developments in decision support systems	

15:05-15:20	238	The impact of indoor residual spraying in different epidemiological settings	
15:20-15:35	239	Anopheles gambiae complex members' susceptibility to Plasmodium falciparum infection in Burkina Faso.	
15:35-15:50	240	The Dielmo project: A 18-year entomological study of malaria transmission and the bionomics of Anopheles gambiae and Anopheles funestus	
15:50-16:05	241	VARIATIONS IN SPECIES COMPOSITION AND INFECTION RATES IN ANOPHELES GAMBIAE S.L. ACROSS ECO-VEGETATIONAL ZONES IN NIGERIA AND CAMEROON	
16:05-16:20	242	Comparative susceptibility of the molecular forms M and S of Anopheles gambiae Theobald (Diptera: Culicidae) to Plasmodium falciparum	
Scientific Session 34: Health system Research III			<i>Lenana</i>
14:35-14:50	243	Nationwide Laboratory Needs Assessment to Identify Gaps in Malaria Laboratory Diagnosis in Kenya	
14:50-15:05	244	Systems effectiveness of a free distribution of long lasting insecticide treated nets in Zanzibar, Tanzania	<i>Lenana</i>
15:05-15:20	245	Development of a strategy to deliver a new malaria control tool: intermittent preventive treatment in Tanzanian infants	<i>Lenana</i>
15:20-15:35	246	PEDIATRIC DIAGNOSES IN A RURAL KENYAN HOSPITAL IMPLEMENTING THE KENYAN INPATIENT PEDIATRIC GUIDELINES	<i>Lenana</i>
15:35-15:50	247	Policy and Implementation status of Community Case Management of Malaria, Pneumonia, Diarrhea, and Neonatal Sepsis in the countdown countries	<i>Lenana</i>
15:50-16:05	248	Pilot implementation of Intermittent Preventive Treatment of malaria in infants (IPTi).	<i>Lenana</i>
Scientific Session 35: Immunology: T Cells and Cytokines			<i>Tsavo Ballroom 1</i>
14:35-14:50	249	IFN-gamma and IL-4 responses induced by promiscuous T-cell epitopes of Plasmodium vivax Merozoite Surface Protein 9 (PvMSP9) in malaria naturally exposed individuals from Brazilian Amazon	
14:50-15:05	250	Analysis of cellular responses to recombinant PfEMP1 domain DBL1 tags dominantly expressed by the homologous parasite isolate	
15:05-15:20	251	IFN-gamma responses to plasmodium falciparum antigens in areas of unstable transmission decrease in periods of very low or absent transmission	
15:20-15:35	252	Plasmodium falciparum GLURP and MSP3 induce higher Interleukin-21 in malaria-exposed compared to non-exposed malaria individuals	
15:35-15:50	253	Interferon-gamma (IFN-) Promoter Polymorphism (-1616A/G) Conditions Acquisition of Parasitemia and Malarial Anemia in Kenyan Children	
15:50-16:05	254	$\gamma\delta$ T cells frequencies in sympatric ethnic groups with different susceptibility to malaria in Burkina Faso	
16:05-16:20	255	Regulatory T-cell profiles in sympatric ethnic groups with different susceptibility to malaria in Burkina Faso	
16:20-16:35	256	Regulatory T cells in human geohelminth infection suppress immune responses to BCG and Plasmodium falciparum	
16:30-17:00	Coffee Break		<i>Delegates Lounge (First Floor)</i>
16:30-17:00	Poster Session D Viewing Posters 355-374, 434-468, 529-537, 653-688, 704-719, 780-801		<i>Delegates Lounge (First Floor)</i>
Controversies IV: Whither African Malaria Research in the 21st Century?			<i>Amphitheatre</i>
17:00-18:30			

Friday, November 6, 2009

Room

	07:00-17:00	Registration	
	07:00-19:00	Internet Access	<i>Safari Lounge</i>
	07:00-18:00	Speaker Ready Room	<i>Caucus 104 (First Floor)</i>
	07:30-19:00	Press Room	<i>Magadi</i>
Plenary 5:			<i>Tsavo Ballroom</i>
	08.15-08.45	Genetically modified mosquitoes for disease control: current status and future plan	
	08.45-09.15	Antimalarials current status and strategies to discover new drugs	
	09.15-09.30	TBA	
	09.30-10.15	TBA	
	10:15-10:45	Coffee Break	<i>Delegates Lounge (First Floor)</i>
	10:15-19:00	Exhibitions Open	<i>The Courtyard</i>
Symposium 40:	AFRO GUIDE		<i>Batian</i>
	10:45-13:15		
Symposium 41:	Improved Tools for Elimination of Malaria in Africa: Research for New Drugs and Innovative Diagnostics		<i>Lake Turkana</i>
	10:45-11:00	Introduction: African Network for Drugs and Diagnostics Innovation (ANDI)	
	11:00-11:10	Strengthening Clinical Research Capacities in Africa	
	11:10-11:20	ANDI - Drug discovery in Africa	
	11:20-11:30	FIND - Innovative diagnostic tools	
	11:30-11:40	ANTIMAL/CRIMALDDI	
	11:40-11:50	Research for Diagnostics	
	11:50-12:00	Natural Products	
	12:00-12:10	Supporting Health Research in Africa - An EU perspective	
	12:10-12:30	Short coffee break IN the room	
	12:30-13:30	Roundtable Q&A session and discussion with panel members...	
	13:30-13:45	Closing Remarks	
Symposium 42:	The RTS,S/AS Malaria Vaccine Candidate at the Pivotal Phase III Evaluation Stage		<i>Amphitheatre</i>
	10:45-10:50	Introduction	
	10:50-11:20	Summary of RTS,S/AS Phase II studies that supported the launch of Phase III	
	11:20-11:50	RTS,S/AS01E Phase III Clinical Trial Design	
	11:50-12:20	Scientific and Public Health considerations for Phase III efficacy trials of malaria vaccines in Africa	
	12:20-12:50	Planning ahead for the first malaria vaccine: The path from development to impacting health	
	12:50-13:15	Open Forum / Discussion / Q & A session	

Scientific Session 36:	Socio-Economic Aspects II		<i>Shimba</i>
10:50-11:05	257	MEASURING THE IMPACT OF SUBSIDIZED BEDNETS IN TANZANIA	
11:05-11:20	258	Effectiveness and Coverage of Malaria Social Marketing Communication Mix	
11:20-11:35	259	Community and Health Care Providers' Perceptions of Malaria Prevention: ITNs and Intermittent Preventive Treatment in Children (IPTc)	
11:35-11:50	260	Reaching the poor with health communication messages: Lessons learned from a National Voucher Scheme for treated nets in Tanzania	
11:50-12:05	261	Historical data from the US suggests affordable malaria treatment could have a significant impact on malaria transmission	
12:05-12:20	262	Rectal artesunate is cost-effectiveness for treating severe childhood malaria	
12:20-12:35	263	Patterns of change in awareness, ownership, and use of ITNs from 2000-2008	
12:35-12:50	551	Acceptability of intermittent preventive treatment versus intermittent screening and treatment for malaria in pregnancy: a qualitative study.	
Scientific Session 37:	Parasite Biology III		<i>Aberdares</i>
10:50-11:05	264	Characterization of antibody responses against adhesive domains of the malaria antigens Pf332 and PfEMP1	
11:05-11:20	265	Developmental shift in var gene transcription in Plasmodium falciparum patient isolates	
11:20-11:35	266	Genetic Diversity of Expressed Plasmodium falciparum var genes from Tanzanian Children with Severe Malaria	
11:35-11:50	267	Mechanisms regulating the surface expression of VAR2CSA and the importance for pregnancy associated malaria	
11:50-12:05	268	Chloroquine-resistance molecular markers (Pfcr1 T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso	
12:05-12:20	269	Polymorphism of Merozoite Surface Protein (MSP)-1 and Merozoite Surface Protein (MSP)-2 of Plasmodium falciparum in Burkina Faso	
12:20-12:35	270	Relationship between the Plasmodium falciparum Pfmdr-1 gene mutations and the responses to the treatment with two artemisinin-based combinations in Burkina Faso.	
12:35-12:50	271	Whether the number of concurrent clones in asymptomatic Plasmodium falciparum infections reflects the degree of host protection needs further elucidation. With the view to establishing the impact of transmission on diversity of P. falciparum infections an	
12:50-13:05	527	PfHsIV: Mitochondrial localization of a prokaryotic protease homolog in Plasmodium falciparum.	
13:05-13:20	528	Multi-faceted impact of MSP-1p42 specific antibodies on blood stages of P. falciparum	
Scientific Session 38:	Parasite-Vector Interaction and Systematics		<i>Tsavo Ballroom 2</i>
10:50-11:05	272	Population Replacement of An. gambiae by An. arabiensis Mediated by the Widespread Use of Insecticide-treated Nets	
11:05-11:20	273	Estimation of infection rates and entomological inoculation rates (EIR) in the African malaria vector: when should CSP-ELISA be the ultimate?	
11:20-11:35	274	Comparison of PCR, ELISA-CSP and direct microscopic observation methods for the detection of Plasmodium falciparum sporozoites in Anopheles gambiae M.	
11:35-11:50	275	Biting and resting behaviour of Anopheles nili in North-Western Burkina Faso	

11:50-12:05	276	Anopheles mosquitoes: not just flying malaria vectors... especially in the field.
12:05-12:20	277	Altitudinal and latitudinal variations in species composition of Anopheles gambiae complex (Diptera: Culicidae) along the volcanic Line of Cameroon
12:20-12:35	278	The Vector Population Monitoring Tool: DNA diagnostics for insecticide resistance monitoring in disease vectors
12:35-12:50	279	Human antibody response to Anopheles gambiae saliva: a new immuno-epidemiological marker to evaluate the efficacy of Insecticides Treated Nets (ITNs)?

Scientific Session 39: Drugs and Resistance: ACTs *Tsavo Ballroom 1*

10:50-11:05	280	Effectiveness of artemether-lumefantrine in underfive children with uncomplicated malaria at community level in rural Tanzania: open label prospective study
11:05-11:20	281	PHARMACOVIGILANCE OF ANTIMALARIAL DRUGS: a prospective study on artesunate-amodiaquine treatment in Senegal
11:20-11:35	282	Community-level deployment of artemether lumefantrine (AL) with rapid diagnostic testing: effect on malaria mortality and health service utilization in a rural setting
11:35-11:50	283	PHARMACOKINETICS OF ARTEMISININ COMBINATION THERAPY IN CHILDREN IN KAMPALA, UGANDA
11:50-12:05	284	Pharmacokinetics of dihydroartemisinin and piperazine in children with uncomplicated malaria in Burkina Faso
12:05-12:20	285	Cochrane review of Artemisinin-based Combination Therapy
12:20-12:35	286	Implications of Price and Availability of ACTs on Malaria Treatment in Uganda
12:35-12:50	287	Comparing different artemisinin-based combination therapies in Uganda; implication for policy
12:50-13:05	288	QUALITY OF ARTESUNATE-CONTAINING ANTIMALARIALS MARKETED IN NIGERIA

Scientific Session 40: Clinical Epidemiology *Tsavo Ballroom 3*

10:50-11:05	289	GSARIMA, a tool for malaria time series analysis during advanced phases of elimination campaigns with low case numbers
11:05-11:20	290	Developing maps of malaria risk and intervention coverage in Kenya
11:20-11:35	292	An updated epidemiology of malaria in Kenyan school children
11:35-11:50	293	Breastfeeding and the Risk of Malaria in Children born to HIV-uninfected and HIV-infected Mothers in Uganda
11:50-12:05	294	REGIONAL INFLUENCE OF ANTIMALARIAL DRUG PRESSURE ON EPIDEMIOLOGY OF MALARIA IN SWAZILAND
12:05-12:20	295	Differential prevalence of Plasmodium infections and cryptic P. knowlesi malaria in humans, Thailand
12:20-12:35	296	The effect of malaria in pregnancy on neonatal and infant mortality in southern Mozambique
12:35-12:50	297	Plasmodium falciparum genotype diversity in symptomatic malaria children under five years living in two different settings in Burkina Faso: Urban and Rural area
12:50-13:05	298	Using demographic surveillance system to record early inadvertent exposure of antimalarial during pregnancy

Scientific Session 41: Immunology: Antibodies *Lenana*

10:50-11:05	299	Acquisition of antibody against VarO, a Plasmodium falciparum rosette-forming variant, in a Senegalese holoendemic rural setting
-------------	-----	--

11:05-11:20	300	Plasmodium falciparum var gene expression patterns in children with different levels of immunity to malaria	
11:20-11:35	301	Are antibody responses to PfEMP-1 reflected by antibody responses to DBLa-tags?	
11:35-11:50	302	Humoral immunity in Mozambican children with severe and uncomplicated malaria	
11:50-12:05	303	Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical outcome in Sudan	
12:05-12:20	304	Humoral Immune Response To Mixed AMA1 Alleles; Multivalent AMA1 Vaccines Induce Broad Specificity	
12:20-12:35	305	Heterologous prime-boost immunizations with different alleles of MSP1 as strategy to overcome allele-specific immunity	
12:35-12:50	306	Antibodies to an invasion-inhibitory epitope on Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) are associated with protection from clinical disease	
12:50-13:05	307	Impact of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine on Immune Responses to Erythrocytic Stage Antigens in Mozambican Children	
13:05-13:20	308	Epstein Barr viral load and Antibodies in children in with malaria	
Scientific Session 42:	MIM Young Investigators		<i>Taifa</i>
10:45-13:15			
13:15-14:30	Lunch		<i>Marquee (in the Lawn)</i>
14:30-18:30	Closing ceremony		<i>Tsavo Ballroom</i>